527 related articles for article (PubMed ID: 16730566)
1. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in Taiwan.
Chou NK; Chen RJ; Ko WJ; Lin HL; Yu SY; Chen YS; Hsu RB; Lee CM; Lin FY; Wang SS
Transplant Proc; 2004 Oct; 36(8):2393-5. PubMed ID: 15561260
[TBL] [Abstract][Full Text] [Related]
3. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
Barnard JB; Thekkudan J; Richardson S; Bittar MN; Martyszczuck R; Hasan J; Khasati N; Keevil B; Yonan N
J Heart Lung Transplant; 2006 May; 25(5):564-8. PubMed ID: 16678036
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.
Iversen M; Nilsson F; Sipponen J; Eiskjaer H; Mared L; Bergan S; Nyström U; Fagertun HE; Solbu D; Simonsen S
J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
Delgado DH; Rao V; Hamel J; Miriuka S; Cusimano RJ; Ross HJ
J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
[TBL] [Abstract][Full Text] [Related]
8. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
Davies RA; Veinot JP; Williams K; Haddad H; Baker A; Donaldson J; Pugliese C; Struthers C; Masters RG; Hendry PJ; Mesana T
Transplant Proc; 2007 Dec; 39(10):3334-9. PubMed ID: 18089382
[TBL] [Abstract][Full Text] [Related]
9. History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion.
Cantarovich M; Barkun J; Giannetti N; Cecere R; Besner JG; Tchervenkov J
Transplant Proc; 2004 Mar; 36(2 Suppl):442S-447S. PubMed ID: 15041383
[TBL] [Abstract][Full Text] [Related]
10. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
Bunnag S; Vareesangthip K; Ong-ajyooth L
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
[TBL] [Abstract][Full Text] [Related]
11. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
Mathias HC; Ozalp F; Will MB; Borland W; Payne C; Kerr M; Lockhart J; Murday AJ
J Heart Lung Transplant; 2005 Dec; 24(12):2137-43. PubMed ID: 16364862
[TBL] [Abstract][Full Text] [Related]
13. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
Kyllönen LE; Salmela KT
Transplantation; 2006 Apr; 81(7):1010-5. PubMed ID: 16612277
[TBL] [Abstract][Full Text] [Related]
14. Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation.
Aumente MD; Arizón JM; Segura J; López A; Albornoz R; Cárdenas M; Segura C
Transplant Proc; 2005 Nov; 37(9):4014-7. PubMed ID: 16386613
[TBL] [Abstract][Full Text] [Related]
15. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
[TBL] [Abstract][Full Text] [Related]
16. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
Caforio AL; Tona F; Piaserico S; Gambino A; Feltrin G; Fortina AB; Angelini A; Alaibac M; Bontorin M; Calzolari D; Peserico A; Thiene G; Iliceto S; Gerosa G
Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
[TBL] [Abstract][Full Text] [Related]
17. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
Akhlaghi F; Gonzalez L; Trull AK
J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
[TBL] [Abstract][Full Text] [Related]
18. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
19. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
[TBL] [Abstract][Full Text] [Related]
20. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients.
Diciolla F; Scolletta S; Berti L; Maccherini M; Federici D; Bernazzali S; Lisi G; Chiavarelli M
Transplant Proc; 2005 Mar; 37(2):1355-9. PubMed ID: 15848719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]